86 related articles for article (PubMed ID: 8521414)
1. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines.
Shapiro GI; Park JE; Edwards CD; Mao L; Merlo A; Sidransky D; Ewen ME; Rollins BJ
Cancer Res; 1995 Dec; 55(24):6200-9. PubMed ID: 8521414
[TBL] [Abstract][Full Text] [Related]
2. p16INK4A participates in a G1 arrest checkpoint in response to DNA damage.
Shapiro GI; Edwards CD; Ewen ME; Rollins BJ
Mol Cell Biol; 1998 Jan; 18(1):378-87. PubMed ID: 9418885
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of p16INK4a in primary tumors and cell lines of head and neck squamous cell carcinoma.
Kim HS; Chung WB; Hong SH; Kim JA; Na SY; Jang HJ; Sohn YK; Kim JW
Mol Cells; 2000 Oct; 10(5):557-65. PubMed ID: 11101148
[TBL] [Abstract][Full Text] [Related]
4. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model.
Kannan K; Sharpless NE; Xu J; O'Hagan RC; Bosenberg M; Chin L
Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1221-5. PubMed ID: 12538879
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of CtIP leads to early embryonic lethality mediated by G1 restraint and to tumorigenesis by haploid insufficiency.
Chen PL; Liu F; Cai S; Lin X; Li A; Chen Y; Gu B; Lee EY; Lee WH
Mol Cell Biol; 2005 May; 25(9):3535-42. PubMed ID: 15831459
[TBL] [Abstract][Full Text] [Related]
6. Retroviral transfer of the p16INK4a cDNA inhibits C6 glioma formation in Wistar rats.
Strauss BE; Fontes RB; Lotfi CF; Skorupa A; Bartol I; Cipolla-Neto J; Costanzi-Strauss E
Cancer Cell Int; 2002 Apr; 2(1):2. PubMed ID: 11983028
[TBL] [Abstract][Full Text] [Related]
7. Derivation of human primary prostate epithelial cell lines by differentially targeting the CDKN2A locus along with expression of hTERT.
Wasserman JS; Fowle H; Hashmi R; Atar D; Patel K; Yarmahmoodi A; Macfarlane AW; Tan Y; Cukierman E; Gligorijevic B; Karami A; Whelan KA; Campbell KS; Graña X
Res Sq; 2024 May; ():. PubMed ID: 38766032
[TBL] [Abstract][Full Text] [Related]
8. Hierarchical discovery of large-scale and focal copy number alterations in low-coverage cancer genomes.
Khalil AIS; Khyriem C; Chattopadhyay A; Sanyal A
BMC Bioinformatics; 2020 Apr; 21(1):147. PubMed ID: 32299346
[TBL] [Abstract][Full Text] [Related]
9. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest.
Goel S; DeCristo MJ; McAllister SS; Zhao JJ
Trends Cell Biol; 2018 Nov; 28(11):911-925. PubMed ID: 30061045
[TBL] [Abstract][Full Text] [Related]
10. From Proteomic Analysis to Potential Therapeutic Targets: Functional Profile of Two Lung Cancer Cell Lines, A549 and SW900, Widely Studied in Pre-Clinical Research.
Korrodi-Gregório L; Soto-Cerrato V; Vitorino R; Fardilha M; Pérez-Tomás R
PLoS One; 2016; 11(11):e0165973. PubMed ID: 27814385
[TBL] [Abstract][Full Text] [Related]
11. The Silencing of CCND2 by Promoter Aberrant Methylation in Renal Cell Cancer and Analysis of the Correlation between CCND2 Methylation Status and Clinical Features.
Wang L; Cui Y; Zhang L; Sheng J; Yang Y; Kuang G; Fan Y; Zhang Q; Jin J
PLoS One; 2016; 11(9):e0161859. PubMed ID: 27583477
[TBL] [Abstract][Full Text] [Related]
12. Control of stress signaling in stem cells: crossroads of stem cells and cancer.
Cho SJ; Koo J; Chun KH; Cha HJ
Tumour Biol; 2016 Oct; 37(10):12983-12990. PubMed ID: 27460084
[TBL] [Abstract][Full Text] [Related]
13. The soybean-derived peptide lunasin inhibits non-small cell lung cancer cell proliferation by suppressing phosphorylation of the retinoblastoma protein.
McConnell EJ; Devapatla B; Yaddanapudi K; Davis KR
Oncotarget; 2015 Mar; 6(7):4649-62. PubMed ID: 25609198
[TBL] [Abstract][Full Text] [Related]
14. Retinoblastoma protein and MyoD function together to effect the repression of Fra-1 and in turn cyclin D1 during terminal cell cycle arrest associated with myogenesis.
Rajabi HN; Takahashi C; Ewen ME
J Biol Chem; 2014 Aug; 289(34):23417-27. PubMed ID: 25006242
[TBL] [Abstract][Full Text] [Related]
15. Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors.
Cho YS; Angove H; Brain C; Chen CH; Cheng H; Cheng R; Chopra R; Chung K; Congreve M; Dagostin C; Davis DJ; Feltell R; Giraldes J; Hiscock SD; Kim S; Kovats S; Lagu B; Lewry K; Loo A; Lu Y; Luzzio M; Maniara W; McMenamin R; Mortenson PN; Benning R; O'Reilly M; Rees DC; Shen J; Smith T; Wang Y; Williams G; Woolford AJ; Wrona W; Xu M; Yang F; Howard S
ACS Med Chem Lett; 2012 Jun; 3(6):445-9. PubMed ID: 24900493
[TBL] [Abstract][Full Text] [Related]
16. E2F inhibition synergizes with paclitaxel in lung cancer cell lines.
Kurtyka CA; Chen L; Cress WD
PLoS One; 2014; 9(5):e96357. PubMed ID: 24831239
[TBL] [Abstract][Full Text] [Related]
17. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
Zhang XH; Cheng Y; Shin JY; Kim JO; Oh JE; Kang JH
Cancer Biol Ther; 2013 Jul; 14(7):597-605. PubMed ID: 23792647
[TBL] [Abstract][Full Text] [Related]
18. The genomics of lung adenocarcinoma: opportunities for targeted therapies.
Greulich H
Genes Cancer; 2010 Dec; 1(12):1200-10. PubMed ID: 21779443
[TBL] [Abstract][Full Text] [Related]
19. Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators.
Mateen S; Tyagi A; Agarwal C; Singh RP; Agarwal R
Mol Carcinog; 2010 Mar; 49(3):247-58. PubMed ID: 19908243
[TBL] [Abstract][Full Text] [Related]
20. Retinoblastoma protein: a central processing unit.
Poznic M
J Biosci; 2009 Jun; 34(2):305-12. PubMed ID: 19550046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
